Drug Metabolism in Drug Design and Development Basic Concepts and Practice

(nextflipdebug2) #1

Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles
of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory
activity in kidney transplant recipients with and without ciclosporin. Nephron
1993;65:410–413.
Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic
interaction between cyclosporine A and atorvastatin in renal transplant recipients.
Am J Transplant 2001;1:382–386. DOI:10.1034/j.1600-6143.2001.10415.x.
Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with
lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369–377.
Baer MR, George SL, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA,
Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase 3
study of the multidrug resistance modulator PSC-833 in previously untreated
patients 60 years of age and older with acute myeloid leukemia: cancer and leukemia
group B study 9720. Blood 2002;100:1224–1232.
Balani SK, Miwa GT, Gan L-S, Wu J-T, Lee FW. Strategy of utilizingin vitroandin
vivoADME tools for lead optimization and drug candidate selection. Curr Top Med
Chem 2005;5:1033–1038.
Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ.
Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide
prodrug, valacyclovir. Biochem Biophys Res Commun 1998;250:246–251.
Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. Effect of pluronic P85 on
ATPase activity of drug efflux transporters. Pharm Res 2004;21:2226–2233.
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-
Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin
Pharmacol Ther 2001;70:311–316.
Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI. Decreased mutation
rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by
the cyclosporin PSC 833. J Nat Cancer Inst 1995;87:1593–1602.
Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: Implications for
predicting drug–drug interactions fromin vitrodata. Curr Drug Metab 2003;4:393–
398.
Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux
transporters and metabolic enzymes. Int J Pharm 2004;277:3–9.
Berg SL, Tolcher A, O’Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan
KH, Balis FM. Effect of R-verapamil on the pharmacokinetics of paclitaxel in
women with breast cancer. J Clin Oncol 1995;13:2039–2042.
Bogman K, Erne-Brand F, Alsenz J, Drewe J. The role of surfactants in the reversal of
active transport mediated by multidrug resistance proteins. J Pharm Sci
2003;92:1250–1261.
Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF,
Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a
modulator of multidrug resistance in patients withcancer. J Clin Oncol 1996;14:610–618.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev
Biochem 2002;71:537–592.
Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug
resistance-associated proteins. J Nat Cancer Inst 2000;92:1295–1302.


186 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS

Free download pdf